Superfluid Dx
Superfluid Dx, Inc. is a life sciences company developing a high-performance, predictive blood-based diagnostic platform using cell-free messenger RNA (cf-mRNA) analysis and machine learning to detect neurodegenerative diseases, primarily Alzheimer's Disease, at early stages. Their minimally invasive liquid biopsy technology enables early detection, disease state monitoring, and therapy guidance, eliminating the need for invasive spinal taps and costly brain scans. The company leverages proprietary methods for characterizing rare mRNA fragments in blood, advanced computational techniques, and a proprietary database to create clinically useful diagnostics. Superfluid is led by experienced executives and scientists, including founders with strong backgrounds in biotech and academia, and is supported by notable investors and grants. Their technology platform has broad applicability across diseases but currently focuses on urgent needs in Alzheimer's diagnostics and treatment selection.
Superfluid Dx
Superfluid Dx, Inc. is a life sciences company developing a high-performance, predictive blood-based diagnostic platform using cell-free messenger RNA (cf-mRNA) analysis and machine learning to detect neurodegenerative diseases, primarily Alzheimer's Disease, at early stages. Their minimally invasive liquid biopsy technology enables early detection, disease state monitoring, and therapy guidance, eliminating the need for invasive spinal taps and costly brain scans. The company leverages proprietary methods for characterizing rare mRNA fragments in blood, advanced computational techniques, and a proprietary database to create clinically useful diagnostics. Superfluid is led by experienced executives and scientists, including founders with strong backgrounds in biotech and academia, and is supported by notable investors and grants. Their technology platform has broad applicability across diseases but currently focuses on urgent needs in Alzheimer's diagnostics and treatment selection.